Lapatinib &trastuzumab shrinks HER2+ bc

besa

http://m.medicalxpress.com/news/2016-03-lapatinib-...

"Approximately a quarter of women diagnosed with HER2 positive breast cancer who were treated with a combination of the targeted drugs lapatinib and trastuzumab before surgery and chemotherapy, saw their tumors shrink significantly or even disappear, according to results from a clinical trial."....

"This has ground-breaking potential because it allows us to identify a group of patients who, within 11 days, have had their tumours disappear with anti-HER2 therapy alone and who potentially may not require subsequent chemotherapy. This offers the opportunity to tailor treatment for each individual woman."...